Research HER
Related Resources for this page:
- Clinical Trials
- Cancer Biomarkers
- Breast Cancer
- A brief history of ADCs
- Breast Cancer
- Current research in ADCs
- Cytotoxic agent
- Slide decks and videos
- HER2 dimerization
- How are ADCs designed to work?
- Glossary
- Monoclonal antibody
- Receptor-Mediated Endocytosis
- Research HDIs
- Research ADCs
- Slide decks and videos
- Stable linker
- Targeting cancers with ADCs
- HER2+ breast cancer
- Trastuzumab Emtansine (T-DM1)
- What are ADCs?
- Lung Cancer
- Ovarian Cancer
- Breast Cancer
- Future Directions
- Antibody-Drug Conjugates
- A brief history of ADCs
- Current research in ADCs
- Cytotoxic agent
- HER Signaling
- How are ADCs designed to work?
- Hypoxic tumor environment promotes angiogenesis
- Glossary
- Monoclonal antibody
- Research ADCs
- Slide decks and videos
- Stable linker
- Summary
- Targeting cancers with ADCs
- Trastuzumab Emtansine (T-DM1)
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- What are ADCs?
- Antibody-Drug conjugates
- Glycoengineered Antibodies
- Non-Antibody Biologics
- Targeted Small Molecules
- Gastric Cancer
- HER1/EGFR as a therapeutic target
- Hypoxic tumor environment promotes angiogenesis
- Summary
- PI3K/Akt/mTOR Signaling
- Therapeutic potential of HER pathways
- Slide decks and videos
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- Vismodegib (GDC-0449) Smoothened Inhibitor
- Traditional Monoclonal Antibodies
- Glossary
- Gastric Cancer
- HER Signaling
- HER1/EGFR as a therapeutic target
- HER2:HER3 dimer
- HER2 as a therapeutic target
- HER3 as a therapeutic target
- Hypoxic tumor environment promotes angiogenesis
- Obinutuzumab (GA101)
- Summary
- Angiogenic Signaling
- Inhibition of HER2 dimerization
- Therapeutic potential of HER pathways
- Slide decks and videos
- VEGF in pancreatic cancer
- VEGF and prognosis in pancreatic cancer
- VEGF and tumor progression in pancreatic cancer
- VEGF expression and liver metastases
- Antibody-Drug Conjugates
Share
Summary: HER Pathways in Cancer
Dysregulation of signaling pathways contributes to cancer
- In cancer, cellular signals may be inappropriately turned on, resulting in the uncontrolled growth and spread of tumor cells3
HER pathways play a key role in the development of many cancers
- The HER family of receptors controls a number of signaling pathways1
- Inappropriate activation of HER signaling pathways has been linked to the development of numerous tumor types, including5,8-11:
- Breast cancer
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic cancer
- Prostate cancer
- Head and neck cancer
- Glioblastoma multiforme
HER signaling pathways are complex
- The multistep process of HER pathway signaling includes1,2:
- Ligand binding
- Receptor dimerization
- Tyrosine kinase domain activation
- Downstream molecular signals
- New preclinical and clinical research continues to expand our understanding of the relationship between HER pathway dysfunction and cancer
HER pathways are potential therapeutic targets
- Because HER pathways are involved in the development of cancer, they may represent therapeutic targets
- There are several strategies to target HER pathways. Targets may include:
- Ligands1
- Extracellular receptor domain (activation and dimerization)12
- Intracellular receptor domain (tyrosine kinase)13
- Downstream signaling molecules1